| Symbol | PBMWW |
|---|---|
| Name | PSYENCE BIOMEDICAL LTD. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 121 RICHMOND STREET WEST PENTHOUSE, TORONTO, None None |
| Telephone | 27744604171 |
| Fax | — |
| — | |
| Website | https://www.psyence.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001985062 |
| Description | Psyence Biomedical Ltd. (Nasdaq: PBM) is the worlds first life science biotechnology company focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. The name Psyence combines the words psychedelics and science to affirm Psyence Biomeds commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. The Company is initially focused on mental health disorders in the context of Palliative Care. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - PSYENCE BIOMEDICAL LTD. <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001376474-26-000435 <b>Size:</b> 6 KB
Read moreNew Form SCHEDULE 13D - PSYENCE BIOMEDICAL LTD. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001213900-26-064484 <b>Size:</b> 17 KB
Read morePsyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Read morePsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Read morePsyence BioMed Positioned as Worlds only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Read morePsyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Read morePsyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Read more